LONDON--(Marketwire - April 28, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) and Genome Research Group (GRG) announced today the Euro Zone launch of its Pathologist Collaborative Research (PCR) Program in support of the groundbreaking Project Boveri: Find the Cure Initiative; as the companies leverage their combined technologies, research knowledge and industry relationships.
The Company will announce programs and specifics for each Euro-Zone country as its lead partner in the area is selected. The Company's goal is to establish a worldwide network of diagnostic and research collaborations with continuous collection of cancer specimen and test result data.
The Company's recently announced merger with GRG prepares the group for a leading role in the new era of cancer research, detection, and therapy.
Earlier this year, the Company launched its groundbreaking PCR program whereby selected pathologists provide cell samples of historical or current patients to the Company for analysis with its chromosomal scanning technology. Full results of the scan and analysis will be provided to the pathologist. Patient information or history is neither required nor supplied for the purpose of this research. The scan results will be compared to the diagnosis of the pathologist. The Company will continuously build its database of results as part of its larger clinical pre-trial efforts.
Research has conclusively and irrefutably demonstrated aneuploidy a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer compliment GRG's non-toxic and non-invasive approaches to cancer therapy and cure research.
The Company's focus on cancer research is further underscored by recent major clinical publications that both validate ChromoCure's chromosomal/aneuploidy theory of cancer and establish the company's detection approach as the forefront of both cancer detection and research.
As a direct result of the Company's recently announced agreement with GRG, ChromoCure recently released expanded specifications and significant capability enhancements of its next generation CS300 Chromosomal Scanner technology to accommodate anticipated increased research demand.
ChromoCure's proprietary Chromosomal Scanning technology has proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. With a 100% effective accuracy and specificity, the company believes its technology superior to other detection approaches presently relied upon by pathologists, including genetic or protein biomarker detection. The Company's technology scans and detects the ultimate 'marker' for cancer guaranteeing 100% accuracy and specificity.
GRG's advanced Therapeutic Modeling Protocols, together with ChromoCure's landmark Chromosomal Scanning Technology, further strengthens the Company's leadership in Cancer Detection, Therapy and Cure by providing on-demand, real-time cancer progression analysis to monitor and determine treatment efficacy.
The Company's recently announced merger with GRG will be of mutual benefit in advancement of their shared objective; as a focused Cancer Therapy and Cure Research & Development organization. The announced merger and acquisition of GRG prepares the group for a leading role in this new era of cancer research, detection and therapy.
The combined entity will possess complementary detection and therapeutic technology and protocols. Management believes the transaction to be of significant long-term shareholder value and furthers the Company's transition to research, technology development, and licensing as a source of significant long-term and recurring revenues and equity appreciation.
The Company believes its technologies provide the foundation for significant advances in diagnosis, therapy and cure. The Company recently announced its Therapy and Cure initiatives with Project Boveri: Find the Cure. Shareholders can expect further updates on research collaborations, laboratory partnerships, and research initiatives.
ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.
About Genome Research Group
The Genome Research Group develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary cancer detection system locates and measures unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has a proven and effective accuracy of 100% for all cancers at all stages. The Company's proprietary Therapeutic Modeling Protocols provide statistical modeling and prediction tools for the measurement and monitoring of cancer progression and remission. The Company also applies its technology and knowledge to cancer cure and therapeutics research. GRG owns proprietary techniques for non-toxic and non-invasive cancer therapy utilizing hypothermic modulation and resonance. GRG's advanced Therapeutic Modeling and Treatment Protocols combined with its industry and medical research collaborations validate its leadership role in Cancer Detection, Therapy and Cure.
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.